Clinical Trials Logo

Pancreatic Cancer Stage II clinical trials

View clinical trials related to Pancreatic Cancer Stage II.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02043730 Completed - Clinical trials for Pancreatic Cancer Stage II

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

GAP
Start date: January 2014
Phase: Phase 2
Study type: Interventional

Pancreatic cancer is the fourth cause of cancer mortality: there are different treatment approaches to locally advanced pancreatic cancer management. Generally, gemcitabine alone is considered a reasonable approach for advanced pancreatic cancer patients but we need a chemotherapeutic regimen able to prevent as much as possible a progression of the disease. Nab-paclitaxel (Abraxane) recently demonstrated an interesting activity profile in advanced pancreatic cancer. A combination of Nab-paclitaxel and gemcitabine has been demonstrated superior to gemcitabine alone in metastatic patients.